- Home
- ACXP vs LRE Comparison
ACXP vs LRE Comparison
Compare ACXP & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- LRE
- Stock Information
- Founded
- ACXP 2017
- LRE 2001
- Country
- ACXP United States
- LRE Japan
- Employees
- ACXP N/A
- LRE N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- ACXP Health Care
- LRE
- Exchange
- ACXP Nasdaq
- LRE Nasdaq
- Market Cap
- ACXP 31.4M
- LRE 29.9M
- IPO Year
- ACXP 2021
- LRE 2023
- Fundamental
- Price
- ACXP $0.88
- LRE $1.76
- Analyst Decision
- ACXP Strong Buy
- LRE
- Analyst Count
- ACXP 1
- LRE 0
- Target Price
- ACXP $12.00
- LRE N/A
- AVG Volume (30 Days)
- ACXP 455.1K
- LRE 18.7K
- Earning Date
- ACXP 03-14-2025
- LRE 01-01-0001
- Dividend Yield
- ACXP N/A
- LRE N/A
- EPS Growth
- ACXP N/A
- LRE N/A
- EPS
- ACXP N/A
- LRE 0.29
- Revenue
- ACXP N/A
- LRE $117,804,154.00
- Revenue This Year
- ACXP N/A
- LRE N/A
- Revenue Next Year
- ACXP N/A
- LRE N/A
- P/E Ratio
- ACXP N/A
- LRE $6.04
- Revenue Growth
- ACXP N/A
- LRE 8.82
- 52 Week Low
- ACXP $0.68
- LRE $1.19
- 52 Week High
- ACXP $4.15
- LRE $13.76
- Technical
- Relative Strength Index (RSI)
- ACXP 49.25
- LRE 43.68
- Support Level
- ACXP $0.68
- LRE $1.68
- Resistance Level
- ACXP $1.25
- LRE $2.08
- Average True Range (ATR)
- ACXP 0.10
- LRE 0.15
- MACD
- ACXP 0.02
- LRE 0.00
- Stochastic Oscillator
- ACXP 35.61
- LRE 41.41
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.